Respiratory prescribing data for NHS Health Boards | Right Decisions

Right Decisions
Respiratory : Quality prescribing strategy - a guide for improvement
Back
Data
Respiratory prescribing data for NHS Health Boards

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

This sction contains some top-level prescribing information comparing NHS Boards. The chart below highlights the cost per treated patient which has decreased by £17.00 in NHS Scotland between 2020/21 and 2022/23.

Respiratory costs per treated patient

Generic prescribing

National and local guidance promotes branded prescribing of all inhalers excluding salbutamol inhalers. This ensures that the correct inhaler device and product is given to the individual (e.g. formulations of inhaled corticosteroids differ in potency). The chart below shows prescribing of generic inhalers across health boards, showing improvements across all boards.

Proportion of generically prescribed inhalers as a proportion of all inhalers (excluding salbutamol)

The numerical data for NTI graphs can also be viewed here.

The most up to date national therapeutic indicator data is available here.